Comparative Pharmacology
Head-to-head clinical analysis: AMMONIA N 13 versus HEPATOLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIA N 13 versus HEPATOLITE.
AMMONIA N 13 vs HEPATOLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia N 13 is a radioactive diagnostic agent that is used as a tracer for positron emission tomography (PET) imaging. After intravenous injection, it distributes in the body and is taken up by cells, particularly in the myocardium and brain, via active transport and passive diffusion. Its accumulation reflects regional blood flow and metabolic activity.
HEPATOLITE is a synthetic hepatocyte growth factor analog that binds to c-Met receptors on hepatocytes, activating MAPK/ERK and PI3K/Akt pathways, promoting hepatocyte proliferation and liver regeneration.
1110-1850 MBq (30-50 mCi) intravenous bolus for PET imaging; single dose per imaging session. No repeated dosing within 24 hours.
Intravenous: 50 mg/kg (ideal body weight) over 60 minutes once daily. Oral: 1000 mg three times daily.
None Documented
None Documented
9–12 minutes (blood) for ammonia; incorporation into glutamine may extend effective half-life for imaging purposes; rapid clearance limits toxicity.
Terminal elimination half-life is 2.5–4 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (CrCl <30 mL/min).
Primary renal excretion; >95% eliminated as unchanged ammonia via glomerular filtration and tubular secretion. Minimal biliary/fecal excretion.
Primarily renal excretion (unchanged drug and major metabolite) accounting for ~70% of elimination; biliary/fecal excretion accounts for ~25%; remainder undergoes minor metabolic clearance.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical